ecrin-mdr-crcClinical2024Colon CancerColorectal CancerColorectal NeoplasmsColon CancerColorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/7898United States7IrinotecanCetuximabAdagrasibECRIN MDRNot yet recruitingfalsePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerTo find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.2024-07-157898NCT05722327